Danone CEO sees potential demand growth for health products alongside GLP-1 weight loss drugs.
Danone CEO Antoine de Saint-Affrique downplayed the threat of weight loss drugs on the food industry, stating that surging demand for drugs like Wegovy and Mounjaro would increase consumer appetite for nutritional products. He told CNBC that Danone sees itself as "extremely complementary" to GLP-1 drugs, suggesting that consumers are likely to incorporate healthy products as part of their weight loss regimen.
April 04, 2024
4 Articles